Clinical trials: Acromegaly
Acromegaly
Non Interventional Study For Patients Treated With Somavert®
This open-label, national, prospective, observational, non-interventional, multi-center, post marketing surveillance study was performed in order to examine the efficacy and safety of Somavert® in treatment of subjects with…
- Trial name
- GPOS (NCT00858143)
- Testing
- Non Interventional Observation
- Volunteers
- 311 people
- Sponsor
- Pfizer
Acromegaly
Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®
Check the pharmacodynamics of the drug octreotide acetate LAR 30 mg imported and distributed by Chemical Laboratory Pharmaceutical Bergamo Ltda.
- Trial name
- NCT01086982
- Testing
- Octreotide acetate LAR, Sandostatin LAR ® (octreotide acetate LAR) 30 MG
- Where
- Brazil
- Volunteers
- 16 people
- Sponsor
- Azidus Brasil
Acromegaly
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
The purpose of this study was to determine the safety, tolerability, and efficacy of IONIS-GHR-LRx subcutaneous (SC) injection as monotherapy in patients with acromegaly.
- Trial name
- NCT04522180
- Testing
- GHR-LRX
- Where
- 22 sites in United States, Estonia and 8 more
- Volunteers
- 34 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Acromegaly
Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
The purpose of the study is to collect data about predictive factors for the efficacy of Lanreotide Autogel in patients with acromegaly in routine clinical practice.
- Trial name
- PLAN-A (NCT04003519)
- Sponsor
- Ipsen
Acromegaly
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months.
- Trial name
- NCT04125836
- Testing
- CAM2029 (octreotide subcutaneous depot)
- Where
- 68 sites in United States, Germany and 9 more
- Volunteers
- 135 people
- Sponsor
- Camurus AB
Acromegaly
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the biological safety and efficacy of using the drug, C2L-OCT-01 PR, 30 mg to treat acromegalic patients.
- Trial name
- NCT00616551
- Testing
- C2L-OCT-01 PR, 30 mg, Octreotide acetate prolonged release, 30 mg
- Where
- 6 sites in Belarus, Hungary and 4 more
- Volunteers
- 65 people
- Sponsor
- Ambrilia Biopharma, Inc.
Acromegaly
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
5 month study comparing SOM230 s.c. and Sandostatin s.c. in acromegalic patients.
- Trial name
- NCT00088582
- Testing
- Pasireotide (SOM230), Octreotide (Sandostatin)
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
A Phase 1 Study of TE-8214 Solution in Healthy Volunteers
This is a Phase 1, first-in-human, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and PK of TE-8214 in healthy volunteers. The study will assess single ascending doses (SAD) of TE-8214.
- Trial name
- NCT06372652
- Testing
- TE-8214 - SAD
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Immunwork, Inc.
Acromegaly
Predictive Factors Study
This is a long term study to evaluate common therapeutic algorithms and possible predictive parameters for Somatuline Autogel treatment in patients with Acromegaly.
- Trial name
- TAPAS (NCT02020499)
- Testing
- Somatuline Autogel® (lanreotide) 60, 90, 120 mg.
- Where
- 6 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Ipsen
Acromegaly
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
The main aim of this study is to assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep sub-cutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via…
- Trial name
- NCT00383708
- Testing
- lanreotide (Autogel formulation), Pegvisomant
- Where
- 24 sites in Czechia, Denmark and 8 more
- Volunteers
- 125 people
- Sponsor
- Ipsen
Acromegaly, Pituitary Gigantism
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in Japanese patients with active acromegaly or pituitary gigantism.
- Trial name
- NCT01673646
- Testing
- Pasireotide LAR
- Where
- 27 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00658879
- Testing
- Somavert (Pegvisomant)
- Volunteers
- 251 people
- Sponsor
- Pfizer
Acromegaly
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.
- Trial name
- NCT00765323
- Testing
- Octreotide Implant, Sandostatin LAR Depot
- Where
- 47 sites in United States, Czechia and 7 more
- Volunteers
- 169 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acromegaly
The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
This study is designed to assess the effect of the different continuous s.c. infusion treatments on the human growth hormone (hGH) levels in untreated acromegalic patients in comparison to a standard dose of octreotide.
- Trial name
- NCT02217800
- Testing
- saline, DG3173, octreotide
- Volunteers
- 8 people
- Sponsor
- Aspireo Pharmaceuticals Limited
Acromegaly
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
The present study is planned as an expanded treatment protocol to provide acromegalic patients for whom medical therapy is appropriate access to pasireotide LAR while regulatory approval for pasireotide is sought.
- Trial name
- ACCESS (NCT01995734)
- Testing
- Pasireotide long acting release formulation
- Where
- 37 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Acromegaly, GEP-NET
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning…
- Trial name
- OXTEND-01 (NCT05364944)
- Testing
- Debio 4126, Sandostatin LAR, Somatuline ATG
- Where
- 14 sites in Denmark, France and 6 more
- Volunteers
- 19 people
- Sponsor
- Debiopharm International SA
Acromegaly
Korean Regulatory Post Marketing Surveillance for Somavert
Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)
- Trial name
- NCT05131100
- Testing
- Somavert
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- Pfizer
Acromegaly
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
The study is designed to investigate the safety, tolerability and efficacy of DG3173 in untreated acromegaly patients. Twenty patients received ascending single doses of DG3173 and one dose of octreotide, the current gold…
- Trial name
- NCT02235987
- Testing
- octreotide, DG3173
- Volunteers
- 20 people
- Sponsor
- Aspireo Pharmaceuticals Limited
Acromegaly
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison…
- Trial name
- OXTEND™-03 (NCT06930625)
- Testing
- Debio 4126
- Where
- 74 sites in United States, Austria and 19 more
- Volunteers
- 119 people
- Sponsor
- Debiopharm International SA
Acromegaly
Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.
- Trial name
- NCT05184231
- Sponsor
- Ipsen